Icd 10 Code For Aml Leukemia

ICD‑10 Code for Acute Myeloid Leukemia (AML): A thorough look for Clinicians, Coders, and Students

Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow that requires precise documentation for treatment planning, reimbursement, and epidemiological tracking. In the United States and many other countries, the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD‑10‑CM) provides the standardized system used to capture diagnoses. Day to day, understanding the exact ICD‑10 code for AML—and its subcategories—ensures accurate billing, supports quality reporting, and facilitates research. This article walks you through the ICD‑10 code for AML leukemia, explains how to apply it correctly, highlights common pitfalls, and answers frequently asked questions.

What Is ICD‑10‑CM and Why It Matters for AML

ICD‑10‑CM is the diagnostic coding system maintained by the World Health Organization (WHO) and adapted by the National Center for Health Statistics (NCHS) for use in the United States. Each alphanumeric code corresponds to a specific disease, condition, or external cause of morbidity. For malignancies like AML, the coding system provides:

• Specificity – distinguishes between disease subtypes, phases (remission, relapse), and laterality where applicable.
• Reimbursement accuracy – drives payment under Medicare, Medicaid, and private insurers.
• Epidemiologic surveillance – enables public health agencies to track incidence, mortality, and trends.
• Clinical research – allows researchers to extract cohorts from electronic health records (EHRs) with confidence.

Because AML is an aggressive hematologic malignancy, precise coding impacts everything from chemotherapy authorization to eligibility for clinical trials.

The Core ICD‑10 Code for Acute Myeloid Leukemia

The primary ICD‑10‑CM code for acute myeloid leukemia is:

C92.0 – Acute myeloid leukemia

This code falls under the chapter “Neoplasms” (C00‑D48), specifically within the block “C91‑C95: Leukemia”. The “C92” subcategory groups all myeloid leukemias, and the final digit “0” denotes the acute myeloid variant.

Key Points About C92.0

• C92.0 is used when the documentation confirms AML without specifying remission status.
• It is a billable code, meaning it can be submitted for reimbursement.
• The code is excludes‑1 for chronic myeloid leukemia (C92.1) and other leukemia types, preventing accidental overlap.

Subcategories: Capturing Remission, Relapse, and Unspecified Status

To reflect the dynamic clinical course of AML, ICD‑10‑CM provides three fifth‑character subcategories under C92.0:

How to Choose the Right Subcode

1. Review the latest clinical note – Look for explicit statements about remission, relapse, or persistent disease.
2. Check laboratory data – Flow cytometry, cytogenetics, and PCR results often indicate remission or relapse status.
3. Consider timing – If the patient is within the first induction cycle and no remission has been declared, use C92.00.
4. Document the rationale – In the medical record, note why a particular subcode was selected; this supports audit defense and coding integrity.

Coding Guidelines Specific to AML

The ICD‑10‑CM Official Guidelines for Coding and Reporting provide several directives that affect AML coding:

1. Code First Underlying Condition When Applicable

If AML develops as a secondary malignancy due to prior chemotherapy or radiation for another cancer, the underlying condition (e.g., prior neoplasm) should be sequenced first, followed by C92.0 as a secondary diagnosis. Example:

• C79.51 – Secondary malignant neoplasm of bone marrow (if applicable)
• C92.01 – Acute myeloid leukemia, in remission

2. Use Additional Codes for Complications

AML often presents with complications such as infection, hemorrhage, or tumor lysis syndrome. These should be coded separately:

• D70 – Neutropenia (if clinically significant)
• J18.9 – Pneumonia, unspecified organism
• E87.2 – Acidosis (tumor lysis)

3. Sequencing for Encounter Type

• For initial encounter (active treatment), use the appropriate C92.0X code as the principal diagnosis.
• For subsequent encounter (follow‑up care after treatment completion), the same malignancy code remains appropriate if the patient is still under active surveillance or maintenance therapy.
• For sequela (late effects), use the appropriate B94.8 or Y85 codes if the condition is a residual effect of a prior neoplasm.

4. Laterality Not Applicable

AML is a systemic disease; laterality modifiers (e.g., right, left) are not used with C92.0 codes.

Common Pitfalls and How to Avoid Them

Even experienced coders can stumble when assigning AML codes. Below are frequent errors and strategies to prevent them.